LRMR
Price
$4.08
Change
+$0.07 (+1.75%)
Updated
Sep 17, 04:59 PM (EDT)
Capitalization
342.36M
62 days until earnings call
SNDX
Price
$14.76
Change
-$0.28 (-1.86%)
Updated
Sep 17, 04:59 PM (EDT)
Capitalization
1.3B
55 days until earnings call
Interact to see
Advertisement

LRMR vs SNDX

Header iconLRMR vs SNDX Comparison
Open Charts LRMR vs SNDXBanner chart's image
Larimar Therapeutics
Price$4.08
Change+$0.07 (+1.75%)
Volume$13.16K
Capitalization342.36M
Syndax Pharmaceuticals
Price$14.76
Change-$0.28 (-1.86%)
Volume$35.06K
Capitalization1.3B
LRMR vs SNDX Comparison Chart in %
Loading...
LRMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
LRMR vs. SNDX commentary
Sep 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LRMR is a StrongBuy and SNDX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 18, 2025
Stock price -- (LRMR: $4.08 vs. SNDX: $14.76)
Brand notoriety: LRMR and SNDX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LRMR: 105% vs. SNDX: 63%
Market capitalization -- LRMR: $342.36M vs. SNDX: $1.3B
LRMR [@Biotechnology] is valued at $342.36M. SNDX’s [@Biotechnology] market capitalization is $1.3B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.34B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LRMR’s FA Score shows that 1 FA rating(s) are green whileSNDX’s FA Score has 1 green FA rating(s).

  • LRMR’s FA Score: 1 green, 4 red.
  • SNDX’s FA Score: 1 green, 4 red.
According to our system of comparison, both LRMR and SNDX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LRMR’s TA Score shows that 6 TA indicator(s) are bullish while SNDX’s TA Score has 5 bullish TA indicator(s).

  • LRMR’s TA Score: 6 bullish, 3 bearish.
  • SNDX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, LRMR is a better buy in the short-term than SNDX.

Price Growth

LRMR (@Biotechnology) experienced а +2.00% price change this week, while SNDX (@Biotechnology) price change was -6.17% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.28%. For the same industry, the average monthly price growth was +6.08%, and the average quarterly price growth was +34.58%.

Reported Earning Dates

LRMR is expected to report earnings on Nov 18, 2025.

SNDX is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+1.28% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SNDX($1.3B) has a higher market cap than LRMR($342M). SNDX YTD gains are higher at: 11.649 vs. LRMR (5.426). LRMR has higher annual earnings (EBITDA): -108.21M vs. SNDX (-314.25M). SNDX has more cash in the bank: 469M vs. LRMR (139M). SNDX has less debt than LRMR: SNDX (1.68M) vs LRMR (4.61M). SNDX has higher revenues than LRMR: SNDX (77.9M) vs LRMR (0).
LRMRSNDXLRMR / SNDX
Capitalization342M1.3B26%
EBITDA-108.21M-314.25M34%
Gain YTD5.42611.64947%
P/E RatioN/AN/A-
Revenue077.9M-
Total Cash139M469M30%
Total Debt4.61M1.68M275%
FUNDAMENTALS RATINGS
LRMR vs SNDX: Fundamental Ratings
LRMR
SNDX
OUTLOOK RATING
1..100
1583
VALUATION
overvalued / fair valued / undervalued
1..100
30
Undervalued
84
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
4443
P/E GROWTH RATING
1..100
1005
SEASONALITY SCORE
1..100
5075

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LRMR's Valuation (30) in the null industry is somewhat better than the same rating for SNDX (84) in the Biotechnology industry. This means that LRMR’s stock grew somewhat faster than SNDX’s over the last 12 months.

LRMR's Profit vs Risk Rating (100) in the null industry is in the same range as SNDX (100) in the Biotechnology industry. This means that LRMR’s stock grew similarly to SNDX’s over the last 12 months.

SNDX's SMR Rating (99) in the Biotechnology industry is in the same range as LRMR (100) in the null industry. This means that SNDX’s stock grew similarly to LRMR’s over the last 12 months.

SNDX's Price Growth Rating (43) in the Biotechnology industry is in the same range as LRMR (44) in the null industry. This means that SNDX’s stock grew similarly to LRMR’s over the last 12 months.

SNDX's P/E Growth Rating (5) in the Biotechnology industry is significantly better than the same rating for LRMR (100) in the null industry. This means that SNDX’s stock grew significantly faster than LRMR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LRMRSNDX
RSI
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
76%
Momentum
ODDS (%)
Bullish Trend 2 days ago
89%
Bearish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 13 days ago
83%
Declines
ODDS (%)
Bearish Trend 9 days ago
88%
Bearish Trend 8 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
Aroon
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
LRMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYMPX197.59N/A
N/A
Rydex Precious Metals H
MRFIX66.35N/A
N/A
MFS Research I
MXHAX12.98N/A
N/A
Empower Large Cap Value Inv II
MACCX18.06N/A
N/A
MoA Catholic Values Index Fund Class
AILLX29.10N/A
N/A
Aristotle Core Equity I-2

LRMR and

Correlation & Price change

A.I.dvisor indicates that over the last year, LRMR has been loosely correlated with OCUL. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if LRMR jumps, then OCUL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LRMR
1D Price
Change %
LRMR100%
+2.00%
OCUL - LRMR
48%
Loosely correlated
-2.17%
ATXS - LRMR
48%
Loosely correlated
+1.79%
EYPT - LRMR
47%
Loosely correlated
+0.29%
SYRE - LRMR
47%
Loosely correlated
+1.82%
ACLX - LRMR
47%
Loosely correlated
-1.20%
More

SNDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, SNDX has been loosely correlated with REPL. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if SNDX jumps, then REPL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SNDX
1D Price
Change %
SNDX100%
-1.86%
REPL - SNDX
51%
Loosely correlated
-1.04%
CGON - SNDX
49%
Loosely correlated
+5.48%
ETNB - SNDX
48%
Loosely correlated
+1.38%
XENE - SNDX
47%
Loosely correlated
+2.86%
NRIX - SNDX
47%
Loosely correlated
+1.54%
More